Funding Round

Modulight Secures $12 Million Seed Round for Light-Based Brain Therapy

StartupHub.ai Staff

By StartupHub.ai Staff, reviewed by Daniel Singer, Editor

2 min read

Modulight Secures $12 Million Seed Round for Light-Based Brain Therapy

Modulight Biotherapeutics announced today the successful closure of a $12.2 million Seed funding round. The financing effort was co-led by Jibe Ventures and LocalGlobe, with active participation from Nexus Neurotech Ventures and several other venture firms. This significant capital injection is specifically designated to accelerate Modulight's novel optogenetic technology pipeline. The company’s immediate plan is to advance its therapeutic candidates toward crucial preclinical milestones, most notably funding the IND-enabling studies required for their initial clinical focus: trigeminal pain.

Core Technology: Precise Light-Based Neuromodulation

The core of Modulight's innovation lies in using light to precisely control specific neurons, a method known as optogenetics. This approach aims to solve the problem of current neurological treatments, which often lack the necessary targeting precision for complex disorders. Modulight employs engineered light-sensitive proteins, or opsins, specifically the proprietary inhibitory opsin called eOPN31 optimized for clinical stability, within targeted cells. This enables circuit-based neuromodulation, allowing for the correction of dysfunctional neural activity exactly where needed. Promising preclinical data already exists across models for pain, epilepsy, and movement disorders, highlighting this precise control capability, which contrasts sharply with the broad, systemic effects seen in existing pharmacological therapies. Nexus NeuroTech Ventures underscored the platform's potential to redefine treatments for circuit-driven brain illnesses.

Clinical Focus and Market Validation

Modulight's initial clinical focus targets trigeminal pain, a severe facial pain condition often resistant to conventional drugs. Consequently, this successful Seed funding round validates the shift toward highly specific, engineering-driven neuroscience solutions. Modulight is now positioned to engage with regulatory bodies as they prepare for eventual human trials. The company's ultimate goal is to transform patient care by delivering fast-acting, site-specific relief for debilitating conditions. Furthermore, establishing this financial foundation in optogenetics signals increasing investor appetite for high-risk, high-reward neuroscience platforms, suggesting a strong market belief in light-based modalities overcoming traditional pharmacological limitations.

Mentioned in this story

Get the free daily brief every morning

Every morning the day's AI news, new AI startups and new funding rounds. Free and takes a few minutes to read, unsubscribe at any time.

Join 64,000 other subscribers.

TopicsBiotechFundingJibe VenturesLocalGlobeModulight BiotherapeuticsNeuromodulationOptogeneticsSeed Round

StartupHub.ai StaffDaniel SingerWritten by StartupHub.ai Staff, Editorial teamReviewed by Daniel Singer, EditorAbout

StartupHub.ai Staff, Editorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.

Daniel Singer, Editor

Daniel Singer is an AI expert who has been writing about, covering and building AI technology since 2018.

More from Daniel Singer

Test your Agent Readiness now

Paste your website. How well ChatGPT, Claude and the other agents can read and use a site, in about a minute.

Watch

The videos behind the news, one flip at a time

The feed mixes the videos from our articles with startup demos and you flip through them like TV channels for free with no signup.